Literature DB >> 16102581

High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.

Friedrich W Cremer1, Mutlu Kartal, Dirk Hose, Jelena Bila, Isabelle Buck, Frauke Bellos, Marc-Steffen Raab, Michaela Brough, Anke Moebus, Hans-Dieter Hager, Hartmut Goldschmidt, Marion Moos, Claus R Bartram, Anna Jauch.   

Abstract

In multiple myeloma, additional copies of chromosome 11 material, reported to confer an unfavorable prognosis, have been found in 20-45% of patients. To assess the incidence and extent of chromosome 11 aberrations, we performed interphase fluorescence in situ hybridization on CD138+ bone marrow plasma cells of 50 newly diagnosed myeloma patients, using seven locus-specific probes for chromosome 11, one for 13q14.3, and a probe set for translocation t(11;14). In 33 of 50 patients, chromosome 11 aberrations were found. Results indicated a marked intraclonal heterogeneity: in 13 patients, trisomy 11; in 10 patients, subclones with trisomy 11 and partial trisomies 11q coexisted; in 6 patients, only a partial trisomy 11q; and in 6 patients, a tetrasomy or partial tetrasomy 11. The coexistence of subclones with varying extent and copy numbers of chromosome 11 material indicates ongoing structural changes and clonal evolution. Hybridization results delineated 11q23 and 11q25 as the most frequently gained regions, which supports a relevant pathogenetic role of genes on 11q23 and 11q25. To confirm the high incidence of 11q23 gains, a further 50 patients (total n=100) were analyzed for 11q23 and 13q14.3. Myeloma with gains of 11q23 showed a low frequency of deletion 13q14.3 and may prove to be a distinct subgroup of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102581     DOI: 10.1016/j.cancergencyto.2005.02.015

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

2.  Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.

Authors:  Faisal M Alseraye; Zhuang Zuo; Carlos Bueso-Ramos; Sa Wang; L Jeffrey Medeiros; Gary Lu
Journal:  Int J Clin Exp Pathol       Date:  2011-04-25

Review 3.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 4.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

5.  In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Authors:  Kyle J Thulien; Andrew R Belch; Tony Reiman; Linda M Pilarski
Journal:  Mol Cancer       Date:  2012-10-19       Impact factor: 27.401

6.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

7.  Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy.

Authors:  Welbert de Oliveira Pereira; Nydia Strachman Bacal; Rodolfo Patussi Correia; Ruth Hissae Kanayama; Elvira Deolinda Veloso; Daniela Borri; Nelson Hamerschlak; Paulo Vidal Campregher
Journal:  BMC Res Notes       Date:  2013-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.